

Michael Deininger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12025938/publications.pdf>

Version: 2024-02-01

35
papers

9,029
citations

279487

23
h-index

377514

34
g-index

35
all docs

35
docs citations

35
times ranked

7865
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807. | 13.9 | 1,738 |
| 2 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051. | 0.8 | 1,188 |
| 3 | Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820. | 0.6 | 1,184 |
| 4 | The development of imatinib as a therapeutic agent for chronic myeloid leukemia. <i>Blood</i> , 2005, 105, 2640-2653. | 0.6 | 1,137 |
| 5 | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37. | 0.6 | 1,117 |
| 6 | Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 3204-3212. | 0.8 | 458 |
| 7 | The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease. <i>Blood</i> , 1998, 92, 3362-3367. | 0.6 | 413 |
| 8 | Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561. | 3.0 | 362 |
| 9 | Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 4210-4218. | 0.8 | 355 |
| 10 | A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2012, 120, 3898-3905. | 0.6 | 154 |
| 11 | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. <i>Blood</i> , 2015, 126, 1551-1554. | 0.6 | 151 |
| 12 | Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050. | 0.6 | 95 |
| 13 | Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949. | 1.7 | 93 |
| 14 | The effect of prior exposure to imatinib on transplant-related mortality. <i>Haematologica</i> , 2006, 91, 452-9. | 1.7 | 87 |
| 15 | The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516. | 1.2 | 83 |
| 16 | Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Leukemia and Lymphoma</i> , 2004, 45, 2197-2203. | 0.6 | 71 |
| 17 | Chronic Myelogenous Leukemia, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1327-1340. | 2.3 | 52 |
| 18 | Resistance to Imatinib: Mechanisms and Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 757-768. | 2.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014, 99, 292-298. | 1.7 | 38 |
| 20 | Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1. | 6.9 | 33 |
| 21 | Curing CML with imatinib—a dream come true?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 127-128. | 12.5 | 31 |
| 22 | Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44. | 0.4 | 25 |
| 23 | Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. <i>Seminars in Oncology</i> , 2008, 35, S1-S17. | 0.8 | 23 |
| 24 | Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2007, 31, 1511-1520. | 0.4 | 15 |
| 25 | Src kinases in Ph+ lymphoblastic leukemia. <i>Nature Genetics</i> , 2004, 36, 440-441. | 9.4 | 14 |
| 26 | Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318. | 1.2 | 14 |
| 27 | CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121. | 2.7 | 14 |
| 28 | Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187. | 3.3 | 8 |
| 29 | Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 604-609. | 0.6 | 7 |
| 30 | Clonal chromosomal abnormalities in CD34+/CD38 ⁻ hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. <i>Leukemia</i> , 2010, 24, 1525-1528. | 3.3 | 6 |
| 31 | Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 1938-1948. | 0.6 | 6 |
| 32 | Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. <i>Leukemia Research</i> , 2011, 35, 831-833. | 0.4 | 4 |
| 33 | High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 886-886. | 0.6 | 3 |
| 34 | Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.. <i>Blood</i> , 2004, 104, 2091-2091. | 0.6 | 1 |
| 35 | Tyrosine Kinase Inhibitors. , 2007, , 477-508. | | 0 |